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Abstract
Recent studies indicate that the release of high mobility group box 1 (HMGB1) following nerve 
injury may play a central role in the pathogenesis of neuropathic pain. HMGB1 is known to 
influence cellular responses within the nervous system via two distinct receptor families; the 
Receptor for Advanced Glycation End-products (RAGE) and Toll-like receptors (TLRs). The 
degree to which HMGB1 activates a receptor is thought to be dependent upon the oxidative state 
Corresponding Author: Fletcher A. White, PhD, Department of Anesthesia, Stark Neurosciences Research Institute, Indiana 
University School of Medicine, 950 Walnut St, R2, Rm 427, Indianapolis, IN 46202, fawhite@iupui.edu.
*Co-first author
The authors declare no conflicts of interest.
Dr. Khanna is presently located at the Department of Pharmacology, College of Medicine, The University of Arizona, Tucson, AZ.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
HHS Public Access
Author manuscript
Brain Behav Immun. Author manuscript; available in PMC 2015 November 01.
Published in final edited form as:
Brain Behav Immun. 2014 November ; 42: 169–177. doi:10.1016/j.bbi.2014.06.199.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
of the ligand, resulting in the functional isoforms of all-thiol HMGB1 (at-HMGB1) acting through 
RAGE, and disufide HMGB1 (ds-HMGB1) interacting with TLR4. Though it is known that dorsal 
root ganglia (DRG) sensory neurons exposed to HMGB1 and TLR4 agonists can influence 
excitation, the degree to which at-HMGB1 signaling through neuronal RAGE contributes to 
neuropathic pain is unknown. Here we demonstrate that at-HMGB1 activation of nociceptive 
neurons is dependent on RAGE and not TLR4. To distinguish the possible role of RAGE on 
neuropathic pain, we characterized the changes in RAGE mRNA expression up to one month after 
tibial nerve injury (TNI). RAGE mRNA expression in lumbar dorsal root ganglion (DRG) is 
substantially increased by post-injury day (PID) 28 when compared with sham injured rodents. 
Protein expression at PID28 confirms this injury-induced event in the DRG. Moreover, a single 
exposure to monoclonal antibody to RAGE (RAGE Ab) failed to abrogate pain behavior at PID 7, 
14 and 21. However, RAGE ab administration produced reversal of mechanical hyperalgesia on 
PID28. Thus, at-HMGB1 activation through RAGE may be responsible for sensory neuron 
sensitization and mechanical hyperalgesia associated with chronic neuropathic pain states.
1. Introduction
Recent studies indicate inflammatory mediators released by nerve injury play a central role 
in the pathogenesis of chronic pain conditions [1]. Although poorly understood, a key 
feature of these inflammatory events is the presence of Danger Associated Molecular 
Patterns (DAMPs; alarmins) [2]. A DAMP of particular interest to the injured nervous 
system is high mobility group protein box-1 (HMGB1; previously known as amphoterin) 
[3]. HMGB1, a nuclear protein that binds DNA and regulates gene expression is structurally 
composed of two tandem DNA-binding domains, Box A and B, and a highly acidic C-
terminal tail composed of a string of aspartate and glutamate residues [4–7]. Originally 
described as a membrane-associated protein that regulated neurite outgrowth during 
development, it is now known that HMGB1 also plays a crucial role in the inflammatory 
responses associated with tissue injury, reparative responses and disease [8–12] and may 
contribute significantly to chronic neuropathic pain states [13, 14].
The action of HMGB1 on different cell types is known to differ dramatically based on the 
oxidation state of the protein. When first released into the extracelluar space, HMGB1 is 
initially in the all-thiol state (at-HMGB1) and is thought to largely act on a member of the Ig 
superfamily, the Receptor for Advanced Glycation End-products (RAGE) [15]. There are 
also reports that at-HMGB1 can form a complex with CXCL12 and act through CXCR4 
[16]. Once present in an oxidative environment, cysteines 23 and 46 of HMGB1 Box A form 
a sulfide bond, effectively producing the disulfide isoform of HMGB1 (ds-HMGB1). ds-
HMGB1 appears to primarily act on the receptor toll-like receptor 4 (TLR4) in order to 
influence the production of inflammatory cytokines [16, 17]. ds-HMGB1 can then be further 
reduced by sulfonation of cysteine 106 in the Box B domain of the ligand, resulting in an 
inert form [18].
It has been suggested that release of HMGB1 from injured neurons can contribute to seizure 
activity associated with epilepsy; however, the receptor responsible for this pathological 
activity is still disputed. [11, 19]. The actions of HMGB1 have also been implicated in both 
inflammatory and neuropathic pain conditions, though it is unclear as to whether the TLR4 
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or RAGE receptor is responsible [13, 14, 20–23]. Endotoxin-mediated TLR4 activation is 
known to directly increase neuronal excitation states in acutely dissociated nociceptive 
neurons [24–27] and administration of xenobiotic TLR4 agonists can produce tactile 
behavioral hypersensitivity in uninjured rodents [27]. Since the effects of HMGB1 could be 
mediated by either TLR4 and RAGE depending on the oxidation state of the protein, we set 
out to determine the contribution of at-HMGB1 on neuronal excitation of nociceptive 
neurons using a small molecule inhibitor of TLR4 [28] and a neutralizing antibody against 
RAGE, 11E6 [29, 30]. Moreover, as little direct evidence exists to support a direct role for 
RAGE in pain, additional studies examined tibial nerve injury (TNI)-induced RAGE 
expression in associated lumbar DRG and the ability of RAGE neutralizing antibody to 
reverse injury-induced behavioral hypersensitivity in the rat across time. Our data indicates 
that at-HMGB1 elicits neuronal excitation via RAGE, in acutely dissociated sensory 
neurons. In addition, the use of the neutralizing RAGE antibody reverses tactile pain 
hypersensitivity. This evidence, together with the increased expression of RAGE in the 
sensory ganglia, identifies a new potential therapeutic target which appears to contribute to 
pathological pain.
2. Methods
2.1 Animals
Pathogen-free, adult female and male Sprague-Dawley (S/D) rats (150–200 g; Harlan 
Laboratories, Madison, WI) were housed in temperature (23 ± 3°C) and light (12-h light: 12-
h dark cycle; lights on at 07:00 h) controlled rooms with standard rodent chow and 
autoclaved tap water available. Experiments were performed during the light cycle. Animals 
were randomly assigned to the treatment groups. All animal related experiments were 
approved by the Institutional Animal Care and Use Committee of Indiana University School 
of Medicine. All procedures were conducted in accordance with the Guide for Care and Use 
of Laboratory Animals published by the National Institutes of Health and the ethical 
guidelines established by the International Association for the Study of Pain.
2.2 Tibial Nerve Injury
All rodents were anesthetized during the procedure with isoflurane (4% induction, 2% 
maintenance). To model neuropathic pain, we performed a tibial nerve injury (TNI) [23; 30; 
58]. S/D rats 150–200g were anesthetized using isoflurane at 4% induction and 2% 
maintenance. Under anesthesia, the right sciatic nerve was isolated under aseptic surgical 
conditions by blunt dissection of the femoral biceps muscle, without damaging the 
epimycium. The sciatic nerve and its three branches were isolated: the sural, common 
peroneal and tibial nerves; only the tibial nerve was tightly-ligated with 5-0 silk and 
transected distal to the ligation. The removal of an additional 2–4mm of distal nerve stump 
was removed in order to prevent re-innervation by the proximal end of the nerve. The 
overlying muscle and skin was then sutured in two separate layers. Sham-injured animals 
were subjected to all preceding procedures with the exception of ligation and transection.
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2.3 Reagents
All reagents were freshly prepared in buffer on day of use. The neutralizing monoclonal 
RAGE antibody (11E6) was generated against the murine C2-domain of RAGE [29, 30] 
(Abbvie Laboratories, Deerfield, IL). Administration of 11E6 or control (Ig1 non-
neutralizing) antibody was given as intraperitoneal injections. A TLR2 [[31]; CU-CPT22] 
and a TLR4 [[28]; compound 15] small molecule inhibitor were synthesized as previously 
described (Kindly provided by Hang Yin, University of Colorado). LPS was purchased by 
Sigma (St. Louis, MO). Non-oxidizable, chemotaxis-HMGB1 (all-thiol) and cytokine-
HMGB1 (disulfide) was purchased from HMGBiotech (Milan, Italy; <1.0 endotoxin per 1 g 
of the protein by the LAL method), and was reconstituted in sterile 0.1% BSA/PBS.
2.4 Behavioral assessment
All rodents were habituated to testing chambers for at least two days. Rodents were 
randomly assigned to sham or injured test groups. All baseline testing occurred before and 
after TNI. The incidence of foot withdrawal in response to mechanical indentation of the 
plantar surface of each hindpaw was measured with a flat-tipped cylindrical probe (Von 
Frey filament) measuring 200 μm in diameter [6; 34]. Von Frey filaments capable of 
exerting forces of 10, 20, 40, 60, 80 and 120 mN with a uniform tip diameter was applied to 
a designated loci present on the plantar surface of the foot. During each test, the rodent was 
placed in a transparent plastic cage with a wire grid floor with ~1°–1 cm openings. The cage 
was elevated so that stimulation was applied to each hind foot from beneath the rodent. The 
filaments were applied in order of ascending force, and each filament was applied 
alternately to each foot. The duration of each stimulus was approximately 1 s and the inter-
stimulus interval was approximately 10–15 s. The incidence of foot withdrawal was 
expressed as a percentage of the 6 applications of each stimulus and the percentage of 
withdrawals was then plotted as a function of force. The von Frey withdrawal threshold was 
defined as the force that evoked a minimum detectable withdrawal observed on 50% of the 
tests given at the same force level. For cases in which none of the specific filaments used 
evoked withdrawals on exactly 50% of the tests, linear interpolation was used to define the 
threshold. Pre-TNI baseline behavioral assessment was established in all rodents. The rats 
were tested pre dose and 1 h post dose on days 7, 14, 21 and 28. Optimum 11E6 dosing was 
established using TNI animals at day 28 using 1, 5, 10, and 15 mg/kg (data not shown). For 
drug studies, all behavioral assessments were performed by blinded pain assessors.
2.5 RNA isolation and RT-qPCR
Lumbar dorsal root ganglia (DRG; L4-L5) were dissected from adult female Sprague 
Dawley rats, frozen in liquid nitrogen, and maintained at −80°C until processed for RNA 
extraction. Total RNA was extracted from the samples using the RNeasy RNA extraction 
and purification kit (Qiagen). Single stranded cDNA was synthesized using reverse 
transcriptase (Bioline) with oligo-dT primers. Quantitative PCR was performed as 
previously described [10]. Briefly, resultant cDNA samples were amplified on an ABI 
PRISM 7900HTSequence Detection System (Applied Biosystems) using the reporter, SYBR 
Green. The PCR reaction was as follows: 1x, 50°C, 2 min; 1x, 95°C, 10 min; 45x, 95°C, 15 
s, 60°C, 1 min; 1x, 25°C, hold. To check for DNA contamination, PCR was run using an 
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L27 (ribosomal housekeeping gene) primer pair, whose PCR product crosses an intron. The 
mRNA level for each gene (x) relative to L27 mRNA (internal control) was calculated using 
the following equation where Ct refers to threshold cycles: mRNA (x%) = 2Ct (L27)-Ct(x) x 
100.
2.6 Western blot analysis
Female animals were sacrificed and transcardially-perfused with saline and tissue was 
removed and frozen immediately with liquid nitrogen and stored at −80°C. The fresh frozen 
L4-L5 DRG tissue samples, ipsilateral to the injury, were homogenized in RIPA buffer with 
protease/phosphatase inhibitors and protein concentration was determined using the BCA 
protein assay (Thermoscientific). Samples (40 μg/lane) were separated by 10% SDS-PAGE 
and transferred to a nitrocellulose membrane. After incubation in 10% non-fat milk blocking 
solution overnight at 4°C, the membrane was incubated with rabbit anti-RAGE (1:1,000; 
Sigma–Aldrich) followed by incubation with horseradish peroxidase-conjugated secondary 
antibodies (Jackson ImmunoResearch). The membrane was probed again with a monoclonal 
anti-β actin antibody (1:5,000; Sigma– Aldrich, St. Louis, MO). Immunopositive bands were 
detected by enhanced chemiluminescence (ECL) and measured by a densitometric analysis 
(UnscanIt; Silk Scientific Inc., Orem, UT, USA).
2.7 Preparation of acutely dissociated dorsal root ganglion neurons
The L4-L6 DRGs were acutely dissociated using methods described by Ma and LaMotte 
[32]. Briefly, L4-L6 DRGs were removed from uninjured female animals. The DRGs were 
treated with collagenase A and collagenase D in HBSS for 20 min (1 mg/ml; Roche Applied 
Science, Indianapolis, IN), followed by treatment with papain (30 U/ml, Worthington 
Biochemical, Lakewood, NJ) in HBSS containing 0.5 mM EDTA and cysteine at 35 C. The 
cells were then dissociated by mechanical trituration in culture media containing 1 mg/ml 
bovine serum albumin and trypsin inhibitor (Worthington Biochemical, Lakewood, NJ). The 
culture media was Ham’s F-12 mixture, DMEM, supplemented with 10% fetal bovine 
serum, penicillin and streptomycin (100 μg/ml and 100 U/ml) and N2 (Life Technologies). 
The cells were then plated on coverslips coated with poly-L lysine and laminin (BD 
bioscience) and incubated for 2–3 h before more culture media was added to the wells. The 
cells were then allowed to sit undisturbed for 12–15 h to adhere at 37° C (with 5% CO2).
Following some in vitro experiments, cells were fixed for 10 minutes using 2% buffered 
paraformaldehyde, washed with saline and incubated with blocking buffer (3% BSA/3% 
horse serum/0.4% Triton-X; Fisher Scientific, Pittsburgh PA) for 1 hour, followed by 
overnight incubation with the goat polyclonal antisera generated against TLR4 L14 
extracellular monoclonal antibody (1:200 dilution; Santa Cruz Biotechnology Inc., Santa 
Cruz, CA, USA) and rabbit anti-RAGE (1:1,000; Sigma–Aldrich) at 4° C. Additional 
monoclonal antibodies were used against CGRP (1;100; Rockland Inc) and IB4 conjugated 
directly to fluorescein isothiocyanate (IB4-FITC; Sigma-Aldrich). After primary incubation, 
secondary antibodies (anti-rabbit, anti-goat or anti-mouse conjugated to CY3 and CY2, 
made in donkey at 1:800; Jackson ImmunoResearch, West Grove, PA) were used to 
visualize cells. Coverslips were washed in PBS for 5 min each (×3), stained with Hoechst 
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33258 nuclear marker (Invitrogen Corporation, Carlsbad CA) and mounted with a PBS/
glycerol solution onto glass slides.
2.8 Ca2+ imaging
The dissociated DRG cells were loaded with fura-2 AM (3 mM, Invitrogen Corp., Carlsbad, 
CA USA) for 25 minutes at room temperature in a balanced sterile salt solution (BSS) (NaCl 
(140 mM), Hepes (10 mM), CaCl2 (2 mM), MgCl2 (1 mM), glucose (10 mM), KCl (5 mM). 
The cells were rinsed with the BSS and mounted onto a chamber that was placed onto the 
inverted microscope. Intracellular calcium was measured by digital video microfluorometry 
with an intensified CCD camera coupled to a microscope and MetaFluor software 
(Molecular Devices Corp., Downington, PA USA). Cells were illuminated with a 150 W 
xenon arc lamp, and the excitation wavelengths of the fura-2 (340/380 nm) were selected by 
a filter changer. Sterile solution was applied to cells prior to HMGB1 application, any cells 
that responded to buffer alone were not used in neuronal responsive counts. HMGB1 (27 
μM) was applied directly into the coverslip bathing solution. HMGB1 was purchased from 
R&D Systems (Minneapolis, MN, USA; <1.0 endotoxin per 1 g of the protein by the LAL 
method), and was reconstituted in sterile 0.1% BSA/PBS. 27 μM of HMGB1 was applied for 
calcium imaging. A period of three minutes was allowed for observation after the treatment 
was introduced to the bath. After HMGB1 application, LPS (1μg/mL) and capsaicin (3 nM) 
were added. Calcium imaging traces were analyzed by two independent analyzers and only 
responses that were in agreement between two individuals were used in the counts.
2.9 Electrophysiology
Sharp-electrode intracellular recordings were obtained from primary afferent neurons 12–18 
hours after dissociation. Coverslips were transferred to a recording chamber that was 
mounted on the stage of an inverted microscope (Nikon Eclipse Ti, Nikon Instruments Inc., 
Melville, NY). The chamber was perfused with a bath solution containing (mM): NaCl 120, 
KCl 3, CaCl2 1, MgCl2 1, Hepes 10, Glucose 10, adjusted to pH 7.4 and osmolarity 300 
mosM. The recordings were obtained at room temperature. Intracellular recording electrodes 
were fabricated from borosilicate glass (World Precision Instruments, Sarasota, FL) and 
pulled on a Flaming/Brown micropipette puller (P-98, Sutter Instruments, Novato, CA). 
Electrodes were filled with 1.0 M KCl (impedance: 40–80 MΩ) and positioned by a 
micromanipulator (Newport Corporation, Irvine, CA). −0.1 nA current injection was used to 
bridge-balance the electrode resistance. Diameter was measured by visual examination prior 
to electrode impalement using a calibrated eyepiece graticule within the microscope. The 
size of the soma to be recorded was classified according to its diameter as small (≤30 μm), 
medium (31–45 μm) and large (≥45 μm). Electrophysiological recordings were performed 
with continuous current-clamp in bridge mode using an AxoClamp-2B amplifier, stored 
digitally via Digidata 1322A interface, and analyzed offline with pClamp 9 software (Axon 
Instruments, Union City, CA). A neuron was accepted for study only when it exhibited a 
resting membrane potential (RMP) more negative than −45 mV. For each neuron isolated 
for study, a continuous recording was obtained for 1 minute without the delivery of any 
external stimulus. Neuronal excitability of small and medium diameter dissociated DRG 
sensory neurons was measured by injecting 1-s current pulses into the soma every 30 s. 
Current was adjusted in order to elicit 1–2 action potentials per current injection under 
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baseline conditions. Non-responding cells were discarded. Following 3 control current 
injections, at-HMGB1 (27 μM) or LPS (1μg/mL) was applied to the coverslip and current 
injections continued every 30 s. Neuronal excitability was measured as number of action 
potentials elicited per current pulse before and immediately after addition of HMGB1 (15 
and 45 s, respectively). If at-HMGB1 increased neuronal excitability, RAGE 11E6 (50 μM), 
TLR4 small molecule inhibitor (compound 15, 50 μM), or TLR2 inhibitor (CU-CPT22, 50 
μM) was added to the bath to determine if at-HMGB1-elicited neuronal excitation could be 
reversed. If LPS increased neuronal excitability, RAGE 11E6 was added to the bath to 
determine if LPS-elicited neuronal excitation could be reversed. Excitation and blocking of 
excitation was analyzed within the first two minutes of application of RAGE 11E6, TLR2 or 
TLR4 inhibitors.
2.10 Statistics
GraphPad Software (LaJolla, CA) was used to determine the statistical significance. Results 
were expressed as mean ± SEM. When only two groups were compared, Student’s unpaired 
t test was used. Multiple comparisons were evaluated by Dunnett’s multiple comparison test 
after one-way ANOVA. p< 0.05 was considered to be statistically significant. GraphPad 
Software was used to determine the statistical significance of differences in calcium 
response among HMGB1 oxidation state groups using Chi-square test with Yates correction 
with p<0.05 set as statistical significance.
3. Results
3.1 Neuronal RAGE-immunoreactivity colocalizes with TLR4, the isolectin IB4 and 
calcitonin-gene related peptide (CGRP) expression
We previously reported that the TLR4 receptor is localized to both peptidergic and non-
peptidergic sensory neurons within the dorsal root ganglia [27]. We examined cells in vitro 
for co-expression of RAGE and TLR4, IB4 and CGRP. Dissociated L4 and L5 DRGs 
removed from naïve animals and cultured for 16–20 hours, exhibited a near complete 
colocalization of TLR4 and RAGE in small and medium diameter neurons (Fig. 1B, C) with 
little to no TLR4 or RAGE immunoreactivity present in non-neuronal cells (Fig. 1A). 
Further examination revealed that there was some colocalization of the RAGE with the non-
peptidergic marker of nociceptive neurons, IB4 (Fig. 1E, F), and the peptidergic nociceptive 
neuronal marker, CGRP (Fig. 1H, I).
3.2 Differential increases in neuronal [Ca2+]i by oxidation state specific HMGB1
To determine whether neuronal RAGE or TLR4 receptors are capable of modulating 
depolarization-evoked Ca2+ transients, we used ratiometric Ca2+ imaging to measure at-
HMGB1 or ds-HMGB1 responses in neurons isolated from rat lumbar DRG. As many LPS-
sensitive sensory neurons are activated by capsaicin [27], we also compared the actions of 
at-HMGB1 and ds-HMGB1 in LPS-sensitive nociceptive and non-nociceptive sensory 
neurons. Virtually all responsive neurons were small (≤30 μm) to medium diameter cells 
(31–45 μm). Exposure to media containing at- or ds-HMGB1 at a 27μM concentration for 3 
minutes was used as a maximal stimulus. This treatment produced a total of 14 of 96 cells 
that were responsive to at-HMGB1, of which only 6 cells responded to both at-HMGB1 and 
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LPS (Table 1). Upwards of 70.1% of at-HMGB1 responsive cells were nociceptive 
(capsaicin-sensitive) (Table 2). These data indicate that many at-HMGB1 responses in vitro 
were likely mediated by the RAGE receptor.
When sensory neurons were subjected to ds-HMGB1, considerably fewer cells exhibited 
calcium transients (7.55%; Table 1). Though there was a decrease in the percentage of total 
responsive cells, 100% of the disulfide HMGB1-responsive neurons responded to LPS 
(Table 1) and only 42% of the assayed cells were sensitive to capsaicin (Table 2). Together, 
these results support the functional expression of both RAGE and TLR4 in nociceptive and 
non-nociceptive DRG neurons in vitro.
3.2 All-thiol HMGB1-elicited increase in sensory neuron excitation is dependent on RAGE 
and not TLR4
HMGB1-induced neuronal hyperexcitability has been recently described in rodent models of 
cerebral ischemia, epilepsy [11, 33] and in DRG sensory neurons in vitro [13]. Though it is 
now known that oxidation state-dependent HMGB1 interactions signal through specific 
receptor types (RAGE receptor or TLR4 receptor), it is largely unknown what receptor is 
responsible for neuronal excitation [16, 17, 34]. To determine the identity of the functional 
receptor by which oxidation state specific forms of HMGB1 can induce changes in sensory 
neuron excitability, we examined cellular responses using current clamp in the presence of 
at-HMGB1. If the cells responded to at-HMGB1, a small molecule inhibitor for TLR4 and 
TLR2, or the RAGE 11E6 antibody was administered followed by repeated current pulses. 
Due to the limited numbers of cells that were responsive to ds-HMGB1 (see Table 1), we 
substituted this form of HMGB1 for the known agonist of TLR4, LPS. Administration of the 
toll receptor antagonists or RAGE 11E6 alone failed to alter resting membrane potentials 
(data not shown).
Repeated current pulses in the presence of at-HMGB1 produced a significant increase in the 
excitability of small diameter sensory neurons when compared to baseline levels (1.4 ± 0.2 
action potentials (APs) for control vs. 5.7 ± 0.4 APs for at-HMGB1) (Fig. 2A). Bath 
exposure to at-HMGB1 in combination with the TLR4 small molecule inhibitor (compound 
15) and repeated current pulses failed to alter repeated current pulse induced APs (5.1 ± 0.4 
APs; n=5; ANOVA, interaction F(3,14) = 52.60, p<0.0001; Bonferroni’s multiple 
comparisons, p>0.05 for at-HMGB1 vs. at-HMGB1 + Comp.15) (Fig. 2A, B). Following 
exposure to at- HMGB1 plus RAGE antibody 11E6, we observed a statistically significant 
decrease in the number of APs when compared with at-HMGB1 alone (1.2 ± 0.1 APs for 
control vs. 6.8 ± 1.3 APs for at-HMGB1 vs. 1.6 ± 0.2 APs for at-HMGB1 + RAGE Ab; n=5; 
ANOVA, interaction F(3,14) = 17.36, p < 0.001; Bonferroni’s multiple comparisons, 
p<0.001 for at-HMGB1 vs. at-HMGB1 + RAGE antibody, 11E6) (Fig 2. C, D). The 
consequences of at-HMGB1 neuronal exposure in the presence of TLR2 inhibitor (CU-
CPT22) were similar to those observed with Compound 15 (1.1 ± 0.1 APs for control vs. 4.3 
± 0.4 APs for at-HMGB1 vs. 3.7 ± 0.2 APs for at-HMGB1 + CU-CPT22; n=5; ANOVA, 
interaction F(3,14) = 32.43, p<0.0001; Bonferroni’s multiple comparisons, p>0.05 for at-
HMGB1 versus at-HMGB1 + CU-CPT22) (Fig. 2E, F).
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3.3 LPS-elicited increase in sensory neuron excitation is not dependent on RAGE
Given the ability of LPS to elicit an inward current in sensory neurons [25–27], we also 
tested whether the LPS-induced neuronal responses were dependent on TLR4 or RAGE. 
Representative recordings and grouped data demonstrate that the excitability of sensory 
neurons was significantly increased by LPS when compared with control levels (Fig. 2G, I). 
We then utilized the RAGE 11E6 antibody to discern the degree to which LPS-induced 
neuron response was dependent on the RAGE receptor. RAGE 11E6 did not alter endotoxin-
induced APs (1.2 ± 0.1 APs for control vs. 4.3 ± 0.4 APs for LPS vs. 4.9 ± 0.4 APs for LPS 
+ RAGE 11E6; n=5; ANOVA, interaction F(3,11) = 32.65, p < 0.0001; Bonferroni’s 
multiple comparisons, p > 0.05 for LPS vs. LPS + RAGE 11E6) (Fig. 2G, H).
A previously reported small molecule inhibitor of TLR4, Compound 15, was then used as a 
chemical probe to further investigate the molecular mechanism of LPS-induced neuron 
response [27, 28]. Similar to our previous observations, Compound 15 completely blocked 
the increased excitability of LPS (1.2 ± 0.1 APs for control vs. 4.9 ± 0.8 APs for LPS vs. 1.7 
± 0.2 APs for LPS + Comp. 15; n=5; ANOVA, interaction F(3,14) = 29.95, p < 0.0001; 
Bonferroni’s multiple comparisons, p < 0.001 for LPS vs. LPS + Comp. 15) (Fig. 2I, J). In 
contrast, Compound 15 demonstrated no effect upon blocking the increased neuronal 
hyperexcitability induced by HMGB1 treatment (Fig. 2A, B).
3.4 RAGE expression in the Lumbar DRG following Tibial Nerve Injury
Previous findings suggest that HMGB1 may be important for neuropathic pain behavior in 
rodents [14] and that HMGB1 can be released for extended periods of time following 
peripheral nerve injury (Feldman et al., 2012). Based on the kinetic breakdown of at-
HMGB1 in different oxidative environments, it is likely that the neuronal RAGE receptor 
may be associated with nociceptive behavior in the rodent. In order to better understand the 
potential influence of RAGE in rodent neuropathic pain models, we studied changes in 
expression of RAGE and other genes known to be modified following peripheral nerve 
injury including the α2β1 auxiliary subunit of the voltage-dependent calcium channel 
(CACNA2D1) and the voltage-gated sodium channel isoform 1.8 (NaV1.8) SCN10A. We 
initially quantified the mRNA level of individual genes in the DRG using quantitative real 
time PCR. Although CACNA2D1 mRNA appeared to increase from naïve levels to post-
injury day 14 and 28, the data was not significantly different (Fig. 3A; n=4, ANOVA, F= 
2.51; p> 0.05). SCN10A mRNA level comparing naive control tissue with post-injury day 
14 and 28 also lacked a statistically different level of significance (Fig. 3B; n=4, ANOVA, 
F= 0.62; p> 0.05). RAGE expression was strongly upregulated by PID 28 when compared to 
both PID 14 and naïve control tissue (Fig. 3C; n=4, ANOVA, F= 8.41; p< 0.05). Given the 
pronounced effect of TNI on RAGE mRNA expression within the L4-L6 DRGs at PID28, 
we next compared the TNI-induced changes on RAGE protein expression levels in L4-L6 
DRGs. Lumbar DRG derived from TNI rodents exhibited a 3-fold increase in RAGE protein 
levels at PID28 (Fig. 4; n=6, ANOVA, F= 12.93; p< 0.05).
3.5 Effects of RAGE 11E6 on pain hypersensitivity in the TNI model of neuropathic pain
To determine the degree to which neutralization of RAGE contributes to chronic pain 
hypersensitivity induced by nerve injury, we performed nociceptive behavioral tests in the 
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presence of a RAGE neutralizing antibody. TNI significantly reduced the pressure and 
tactile withdrawal thresholds of the hind paw on the ipsilateral side (Fig. 5; n=3, 70.54 ± 
1.37 mN; p>0.05) and a single systemic injection of RAGE 11E6 (10 mg/kg) had no effect 
on uninjured rodents (data not shown). Systemic administration of RAGE 11E6 failed to 
affect tactile hyperalgesia when administered at 7, 14, or 21 days. However, tactile 
withdrawal thresholds of the hind paw ipsilateral to TNI at PID28 were transiently returned 
to baseline levels by 4 hours (Fig. 5; n=6–8, 58.33 ± 2.21 mN, ANOVA; p< 0.01). The 
finding that RAGE 11E6 did not elevate tactile hypersensitive levels above the pre-injury 
state shows that the animals ability to detect noxious tactile stimulus was not altered by the 
use of the antibody. Similar observations of RAGE 11E6 behavioral reversal in age-matched 
male rodents subjected to TNI was also observed (data not shown; n=6–8 per post injury 
time point).
4. Discussion
Our study provides evidence that the ligand at-HMGB1 acting through RAGE is a critical 
regulator of nociceptive signaling and sensitization in vitro. Moreover, as ongoing pain 
following peripheral nerve injury is thought to be maintained in part by activity in sensitized 
primary afferent neurons and could be influenced by an injury-induced upregulation of de 
novo receptors [35], latent upregulation of RAGE in the DRG corresponds with the ability of 
a monoclonal antibody against RAGE to modulate neuropathic pain-related behavior in the 
rat.
4.1 HMGB1 receptor signaling in the nervous system
There is growing evidence that the presence of cytosolic HMGB1 in the nervous system 
following insult contributes to neuropathologic neuronal excitability, including epilepsy, 
neuropathic pain and migraine [11, 13, 36]. A number of pain studies have demonstrated 
that the perisciatic or intrathecal administration of HMGB1 can produce rapid and transient 
mechanical and thermal hyperalgesia in rodents [14, 20, 21]. However, given the possibility 
that either of the two isoforms of HMGB1 may be present after injury to the nervous system 
[37], there is little knowledge regarding which of the cogent HMGB1 receptors, RAGE and 
TLRs, contribute to changes in neuropathological conditions. Although sensory neurons 
exhibit both functional TLR4 and RAGE receptors, our studies show that RAGE 11E6 
completely inhibits at-HMGB1-dependent neuronal excitability in vitro. In contrast, there is 
no evidence to suggest that at-HMGB1 activates neuronal TLR4, considering a small 
molecule inhibitor of TLR4 failed to reverse at- HGMB1 elicited neuronal excitability in 
vitro.
4.2 RAGE signaling in the nervous system
HMGB1 acting through RAGE was initially implicated in neurite outgrowth in embryonic 
neurons and migration of numerous immune and non-immune cells types during states of 
inflammation [38–41]. The relevance of HMGB1/RAGE to inflammation is relatively well 
described for the pathogenesis of diabetes, cardiovascular disease and various cancers [42]. 
Whether HMGB1 activation of neuronal RAGE and the resultant increase in neuronal 
excitability during or following nerve injury-induced inflammation, represents a 
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neuropathological consequence, is generally unknown. Initial reports in mice suggest that 
pharmacological and genetic blockade of RAGE impairs both innate immune response and 
nerve regeneration following sciatic nerve crush [43, 44]. Though the degree to which this 
injury altered tactile hyperalgesic behavior was not tested, the potential effects may not have 
manifested measurable changes given that both the nerve conduction velocities and gait 
analysis were tested for only three weeks post-nerve injury while the behavioral effects of 
increased RAGE expression in the rat DRG following peripheral nerve injury could only be 
adequately assayed at four weeks. A mechanism that might account for this latent change in 
RAGE could be due to a HMGB1 feed forward mechanism that exists in some immune cells 
and could serve to increase the levels of RAGE ligands and subsequently increased RAGE 
expression [45].
4.3 Oxidation State dependent HMGB1 signaling in the nervous system
Functional delays in the expression of RAGE in the affected DRG and the latent ability of 
RAGE neutralization to reverse tactile behavior in the rodent may also be dependent on 
changes in the state of HMGB1. It is well known that HMGB1 may form a complex with 
other molecules to enhance proinflammatory responses, including LPS, IL-1, bacterial 
DNA, CXCL12, and viral RNA [46–48]. The state-dependent characteristics that contribute 
to protein/receptor interaction appear to depend on the molecular properties of three cysteine 
residues; the redox state of cysteine (C) 106, and a disulfide bond between C23 and C45 [49, 
50]. For example, during active inflammation the predominant form of HMGB1 is C106 
thiol (all-thiol) and disulfide bond C23–45 (disulfide-HMGB1); however, when 
inflammation begins to subside, HMGB1 terminally oxidizes its cysteine residues and 
greatly diminishes biological activity (oxidized-HMGB1) [51–53]. Moreover, an oxidizing 
environment following inflammation or injury may promote HMGB1 cytokine activity [54]. 
These changes in HMGB1 conformation over time combined with the feed forward 
expression mechanisms that exist may account for the delayed influence observed in this 
neuropathic pain model.
Several published works have shown the importance of HMGB1 in the propagation of pain 
pathology, and when combined with the duality of function of the HMGB1 molecule, the 
change of the expression of the RAGE receptor as time progresses in vivo, as well as the 
efficacy of the antibody against the RAGE receptor with pain reversal, the conclusion can be 
drawn that RAGE and its signaling pathway are integral to pain pathology at later stages. 
Results of further study regarding the RAGE signaling axis may uncover targets for novel 
therapeutics and possibly have direct impact upon current clinical practice, through the 
discovery of potential biomarkers for pathologies of chronic inflammation, and through 
better understanding of the mechanisms of inflammation as they relate to disease. RAGE 
could possibly be a lynchpin to understanding the complete pathway leading to the 
pathogenesis of neuropathic pain.
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Figure 1. RAGE, TLR4, IB4 and CGRP immunohistochemistry in primary sensory neuron 
cultures
Images depicting corresponding images of the cell nucleus label DAPI (A), RAGE (B) and 
TLR4 (C). Note that the majority of RAGE immunoreactive neurons are also positive for 
TLR4 (yellow arrows indicates co-expression). Corresponding images of DAPI (D), RAGE 
(E), and the non-peptidergic marker of nociceptive neurons, IB4 (F). A minority of IB4 cells 
exhibit RAGE (yellow arrow indicates co-expression). Corresponding images of DAPI (G), 
RAGE (H), and the peptidergic marker of nociceptive neurons, CGRP (I). Note that there 
are numerous RAGE immunoreactive neurons which are also positive for CGRP. Scale bar 
is 50 μm.
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Figure 2. RAGE neutralizing antibody, but not the TLR4 small molecule inhibitor, Compound 
15, suppresses at-HMGB1-dependent neural excitation in acutely dissociated sensory neurons
Current clamp recordings were performed on small-to-medium (>30 μm – >40 μm) diameter 
lumbar 4–5 DRG neurons from naive rats. Firing of 1–2 action potentials (APs) was elicited 
by a 1 second depolarizing current injection (ranging from 0.1 to 2.0 nA depending on the 
cell) every 30 seconds. Representative recordings demonstrating that application of at-
HMGB1 (27μM) increases the number of elicited action potentials in DRG sensory neurons 
is not reversed by TLR4 small molecule inhibitor (compound 15) (A) or a TLR2 inhibitor 
(CU-CPT22) (E). In contrast, exposure to RAGE antibody effectively suppresses at-
HMGB1-dependent action potential (C). Group data showing that compound 15 (B) and 
CU-CPT22 (F) do not reverse at-HMGB1-elicited increase in DRG neuron action potential 
firing while RAGE Ab does reverse increased excitation (D). Representative recording 
demonstrating that application of LPS (1 μg/ml) increases the number of elicited action 
potentials in DRG sensory neurons which is unaffected by RAGE antibody (G). In contrast, 
the neuronal effects of LPS can be suppressed with compound 15 (I). Group data showing 
that compound 15 (J), but not RAGE Ab (H), reverses LPS-elicited increase in DRG neuron 
action potential firing. (Ligand treatment compared to receptor inhibitor; *p < 0.05)
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Figure 3. Tibal Nerve Injury (TNI) alters the expression of neuronal transcripts in dorsal root 
ganglion (DRG) derived from TNI rats
(A–D) RT-PCR analysis showing the mRNA expression profile of CaV alpha2delta1 (A) 
NaV1.8 (B) and RAGE (*p< 0.05) (C) at different time points following TNI; post injury 
day (PID) 14 and PID 28 (n=3). RT-PCR data were analyzed using the Ct method and 
mRNA expression levels are expressed relative to L27-ribosomal housekeeping gene.
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Figure 4. RAGE protein expression following TNI at post injury day 28
Immunoblot of RAGE in L4/5 DRGs from naïve, sham injured and TNI ipsilateral to the 
injury at [PID] 28 (n=3, sham versus injury; *p< 0.05). Actin was used as a loading control 
to which samples were normalized.
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Figure 5. Decreased tactile hyperalgesia following intraperitoneal injection of a neutralizing 
RAGE antibody in tibial nerve-injured rats at Day 28
Paw withdrawal threshold (PWT) in rodents subjected to TNI (n = 6–8, white bars) were 
significantly reduced when compared with pre-TNI thresholds (n = 6–8, black bar) for at 
least 28 days. Administration of control, non-neutralizing antibody did not alter PWT at 
baseline or after TNI at 7, 14, 21 or 28 days (n = 6–8, CT Ab; gray bars). A humanized 
monoclonal antibody to RAGE (RAGE Ab; 10 mg/kg body weight; n = 6–8 each) was 
administered intraperitoneally and ipsilateral PWT was assessed using the von Frey filament 
test. Behavior was tested at 1 h post injection and again at 4 hours (data not shown). A 
single injection of RAGE Ab did not produce a change in PWT at TNI PID 7, 14, and 21 
(striped bar) that differed from pre-RAGE Ab (white bars). At TNI PID 28 a single injection 
of RAGE Ab successfully reversed TNI decreases in PWT when compared with pre-RAGE 
Ab treatment (*p< 0.05).
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Table 1
Differential increases in neuronal [Ca2+]I by oxidation specific HMGB1
Percent Total Neurons Percent Responsive to LPS
at-HMGB1 14.58% (14/96) 43% (6/14)
ds-HMGB1 7.55% (8/106) 100% (8/8)
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Table 2
Population of nociceptive neurons via capsaicin sensitivity responsive to HMGB1 isoforms
N = 217 Percent Responsive to capsaicin
at-HMGB1 70.1%
ds-HMGB1 42%
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